Embla Medical hf: Interim Report Q4 2024

Interim report Q4 2024 Interim report Q4 2024 COPENHAGEN, Denmark , Feb. 5, 2025 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "Sales in Q4 2024 amounted toUSD 225 million, where our organic sales growth was 5% for the quarter and local currency growth was 8%. The continued strong momentum we have seen throughout the year in our Prosthetics & Neuro Orthotics business continued to drive our growth, supported by good growth contribution across all our...

COPENHAGEN, Denmark, 05/02/2025 (informazione.news - comunicati stampa - salute e benessere)

COPENHAGEN, Denmark , Feb. 5, 2025 /PRNewswire/ --

Embla Medical will host a conference call February 5, 2025 , at .

The event will be hosted by Sveinn Solvason , President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly and full year results and will be held in English.

Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors

To participate in the telephone conference, please use the dial-in details provided below:

DK: +45 78 76 84 90

SE: +46 31-311 50 03

UK: +44 20 3769 6819

US: +1 646 787 0157

Participant access code: 274982

The webcast will be available through following link:  Embla Medical Q4/FY 2024 webcast

Klaus Sindahl , Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134

If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors

Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women's Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com

Embla Medical was formerly listed as Össur (OSSR) on Nasdaq Copenhagen until 8 April 2024 .

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--interim-report-q4-2024,c4100604

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/embla-medical-hf-interim-report-q4-2024-302368616.html